ACSS2 and obesity due to melanocortin 4 receptor deficiency: As ACSS2 to be a therapeutic target for obesity, we further discovered that oral D-mannose rapidly targeted adipose tissues and enhanced nuclear ACSS2 level by activating AMPK and enhanced energy expenditure to combat high fat diet (HFD)-induced obesity, liver lipid dysfunction and insulin resistance.